Spatial Multiomics Market by Molecular Modality (Spatial Transcriptomics, Spatial Proteomics, Spatial Genomics, Spatial Epigenomics), Multiomic Combination, Technology, Spatial Resolution, Product & Service, Sample Type, Application, End User, and Geography - Global Forecast to 2036

Spatial Multiomics Market Size

The global Spatial Multiomics Market was valued at USD 0.83 billion in 2025 and is projected to reach USD 0.95 billion in 2026. The market is expected to reach USD 3.5 billion by 2036, registering a CAGR of 13.9% during the forecast period (2026-2036).

• The global Spatial Multiomics Market is projected to reach USD 3.5 billion by 2036, driven by increasing demand for spatially resolved biological analysis and growing adoption of precision medicine.
• North America is expected to account for the largest market share in 2026, while Asia-Pacific is projected to register the fastest growth during the forecast period.
• By molecular modality, Spatial Transcriptomics is expected to account for the largest market share, whereas Spatial Proteomics is projected to witness the fastest growth through 2036.
• By application, Oncology is expected to dominate the market, holding an estimated 47.6% share of the closely related spatial genomics and transcriptomics segment in 2025, while Immunology is projected to register the highest CAGR during the forecast period.
• 10x Genomics' August 2025 launch of Xenium Protein, which enables simultaneous detection of RNA and protein within the same tissue section in a single automated run, illustrates the platform-level shift toward true multiomic spatial profiling that is expanding the market beyond single-modality spatial transcriptomics.
• Within the broader multiomics market, spatial omics is the fastest-growing method segment, expanding at a 13.8% CAGR, underscoring the outsized role spatial multiomics is playing in overall omics market growth.

The Spatial Multiomics Market comprises the instruments, consumables, software, and services used to simultaneously profile multiple molecular layers, including transcriptomics, proteomics, genomics, epigenomics, and metabolomics, while preserving their spatial context within intact tissue architecture. Unlike conventional dissociative omics techniques that lose spatial information during tissue processing, spatial multiomics platforms enable researchers to map gene expression, protein abundance, and other molecular features directly onto tissue sections, supporting applications across oncology, neuroscience, immunology, drug discovery, and precision medicine at single-cell and increasingly subcellular resolution.

The market is undergoing a shift from single-modality spatial profiling toward integrated multiomic platforms capable of capturing several molecular layers from the same tissue section. This transition was reinforced in August 2025 when 10x Genomics launched Xenium Protein, expanding its Xenium platform to enable simultaneous measurement of RNA and protein in the same tissue section. The company subsequently reported more than 1,000 Xenium instruments placed globally by the end of 2025, highlighting the expanding installed base for high-resolution spatial biology and creating a substantial platform base for adoption of additional multiomic capabilities. In February 2026, Singular Genomics launched its G4X Spatial Sequencing platform, designed to integrate spatial transcriptomics with protein and other molecular measurements while substantially increasing spatial profiling throughput. These developments reflect the industry's transition from single-layer spatial profiling toward integrated measurement of multiple molecular features within preserved tissue architecture, increasing the value of spatial multiomics for tumor microenvironment characterization, biomarker discovery, and translational research.

The increasing scale of spatial datasets is also strengthening demand for integrated computational analysis. Modern spatial platforms can generate measurements across hundreds or thousands of genes and proteins at cellular or subcellular resolution, requiring advanced computational tools for image analysis, segmentation, multimodal data integration, and biological interpretation. The convergence of high-throughput spatial sequencing, multiplexed protein detection, and AI-enabled analytics is therefore expected to accelerate adoption of spatial multiomics platforms across pharmaceutical research, academic institutions, and precision medicine programs.

Increasing Demand for Spatially Resolved Biological Analysis

Growing recognition that conventional dissociative omics techniques lose critical information about cellular location and tissue architecture is driving demand for spatial multiomics platforms. Researchers increasingly require spatially resolved data to understand cell-cell interactions, tissue heterogeneity, and microenvironment biology that bulk and single-cell dissociative methods cannot capture, directly expanding demand for spatial transcriptomics, proteomics, and multiomic integration platforms.

Growing Adoption of Precision Medicine

The expanding role of precision medicine in patient stratification and treatment selection is driving adoption of spatial multiomics technologies capable of characterizing individual patient tissue samples in molecular detail. As spatial biomarker discovery moves toward clinical translation, pharmaceutical and biotechnology companies, which accounted for 44% of the broader multiomics market in 2025, are increasingly incorporating spatial multiomics into biomarker validation and patient stratification workflows.

Market Restraints

High Cost of Spatial Multiomics Platforms

Spatial multiomics instruments, consumables, and per-sample assay costs remain substantially higher than conventional bulk or single-cell dissociative omics techniques. These high costs, spanning instrument capital expenditure, specialized reagents and probes, and computationally intensive data analysis, can limit adoption among smaller academic laboratories and constrain the pace of platform deployment outside well-funded pharmaceutical and translational research institutions.

Lack of Standardization Across Platforms

The proliferation of distinct spatial multiomics technologies, spanning sequencing-based, imaging-based, and hybrid imaging-sequencing platforms, has resulted in limited standardization across instrument vendors, data formats, and analysis workflows. This lack of standardization complicates cross-study comparisons and data integration, slowing the pace at which spatial multiomics findings can be validated and translated into clinical applications.

Market Opportunities

Growth of Single-Cell and Subcellular-Resolution Spatial Multiomics

The continued advancement of spatial multiomics platforms toward single-cell and subcellular resolution represents a significant opportunity for the market. As platforms such as Xenium Protein and G4X push toward finer spatial resolution while simultaneously capturing multiple molecular modalities, researchers gain the ability to resolve increasingly granular cellular and subcellular biology, creating new demand across oncology, neuroscience, and immunology research applications.

AI-Based Spatial Multiomics Data Analysis

The growing application of artificial intelligence and machine learning to spatial multiomics data analysis presents a substantial opportunity for software and bioinformatics providers. As highlighted by collaborations such as Complete Genomics' partnership with BioTuring to integrate SpatialX, a deep-learning tool for multi-technology spatial data analysis, AI-based platforms are increasingly critical to managing the data integration and normalization challenges inherent in combining multiple spatial molecular modalities.

Market Challenges

Integration of Heterogeneous Molecular Datasets

Combining data from different molecular modalities, such as transcriptomics, proteomics, and epigenomics, captured through different technologies and at different resolutions within a single tissue section remains a significant technical challenge. Achieving accurate co-registration and biologically meaningful integration of these heterogeneous datasets requires sophisticated bioinformatics approaches that are still maturing across the industry.

Balancing Spatial Resolution and Molecular Coverage

Spatial multiomics platforms face an inherent tradeoff between spatial resolution and the breadth of molecular targets that can be simultaneously profiled, with higher-resolution subcellular platforms often supporting fewer molecular targets than lower-resolution whole-transcriptome approaches. Balancing this tradeoff to meet the specific requirements of different research applications remains a persistent challenge for platform developers and end users alike.

Market Trends

Convergence Toward Integrated Multiomic Platforms

The market is witnessing a clear shift from single-modality spatial profiling toward platforms capable of capturing multiple molecular layers from the same tissue section, exemplified by 10x Genomics' Xenium Protein launch enabling simultaneous RNA and protein detection and Singular Genomics' G4X platform positioned as the industry's highest-throughput spatial multiomics system. This convergence is reducing the need for serial sectioning and separate single-modality experiments, improving both data quality and cost efficiency for researchers.

Rising Integration of AI and Deep Learning in Spatial Data Analysis

Spatial multiomics data analysis is increasingly incorporating AI and deep learning tools to manage the scale and complexity of multi-modal spatial datasets, as illustrated by Complete Genomics' collaboration with BioTuring to integrate its SpatialX deep-learning platform. This trend reflects the broader recognition that the computational and bioinformatics challenges of spatial multiomics are becoming as significant a differentiator among platform providers as the underlying wet-lab technology itself.

Segment Analysis

Market Analysis by Molecular Modality

Based on molecular modality, the global Spatial Multiomics Market is segmented into Spatial Transcriptomics, Spatial Proteomics, Spatial Genomics, Spatial Epigenomics, Spatial Metabolomics, Spatial Lipidomics, and Other Molecular Modalities.

In 2026, Spatial Transcriptomics is expected to account for the largest market share, owing to its position as the most established and widely adopted spatial biology technique, led by platforms from 10x Genomics and other leading vendors. However, Spatial Proteomics is projected to register the fastest growth during the forecast period, driven by increasing demand for protein-level tissue characterization in immuno-oncology and immunology research.

Market Analysis by Technology

Based on technology, the market is segmented into Sequencing-Based Technologies, Imaging-Based Technologies, Hybrid Imaging-Sequencing Technologies, and Other Technologies.

In 2026, Imaging-Based Technologies are expected to account for the largest market share, supported by their widespread use in multiplexed fluorescence imaging and imaging mass cytometry platforms for high-plex spatial profiling. However, Hybrid Imaging-Sequencing Technologies are projected to register the highest CAGR during the forecast period, as platforms increasingly combine both approaches to capture broader molecular coverage alongside high spatial resolution.

Market Analysis by Product & Service

Based on product and service, the market is segmented into Instruments, Consumables, Software, and Services.

In 2026, Consumables are expected to account for the largest market share, due to the recurring-revenue nature of assay kits, reagents, probes, and spatial barcoding consumables required for each experimental run. However, Software is projected to register the fastest growth during the forecast period, driven by rising demand for multiomic data integration, AI/ML analytics, and spatial data visualization platforms.

Market Analysis by Application

Based on application, the market is segmented into Oncology, Neuroscience, Immunology, Drug Discovery & Development, Precision Medicine, Developmental Biology, Infectious Diseases, Cardiovascular Research, and Other Applications.

In 2026, Oncology is expected to account for the largest market share, due to strong demand for tumor microenvironment and tumor heterogeneity characterization. However, Immunology is projected to register the highest CAGR during the forecast period, in line with the 14.2% CAGR reported for immunology and infectious disease applications within the broader spatial genomics and transcriptomics market.

Market Analysis by End User

Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Translational Research Institutes, Clinical Research Organizations, Hospitals & Clinical Laboratories, Diagnostic Companies, Government & Research Organizations, and Other End Users.

In 2026, Pharmaceutical & Biotechnology Companies are expected to account for the largest market share, owing to substantial R&D investment in spatial biomarker discovery and drug development. However, Diagnostic Companies are projected to register the highest CAGR during the forecast period, as spatial biomarkers move closer to clinical translation and diagnostic application.

Based on geography, the global Spatial Multiomics Market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

In 2026, North America is expected to account for the largest share of the global Spatial Multiomics Market, supported by strong biomedical research funding, a high concentration of pharmaceutical and biotechnology companies, and leading spatial biology platform manufacturers in the United States. The U.S. National Institutes of Health (NIH) received approximately USD 48.4 billion in discretionary funding for FY2025, providing substantial support for genomics, single-cell biology, cancer research, and other research areas that increasingly incorporate spatial multiomics technologies. In addition, the National Cancer Institute's Human Tumor Atlas Network (HTAN) continues to generate large-scale spatial and single-cell datasets for mapping tumor architecture and molecular interactions, supporting demand for advanced spatial profiling and multiomic analysis capabilities.

However, Asia-Pacific is projected to register the highest CAGR during the forecast period, driven by expanding biomedical research infrastructure, increasing government support for precision medicine, and rising adoption of spatial biology technologies across China, Japan, South Korea, and India. China's 2025–2026 national biomedical research programs continue to prioritize precision medicine, multiomics, and advanced molecular diagnostics, while Japan's AMED-supported research programs are funding genomic and multiomic approaches for disease research and drug discovery. The rapid expansion of biotechnology and pharmaceutical R&D in China, Japan, South Korea, and India is also increasing the installed base of high-throughput sequencing and single-cell analysis systems, creating a broader infrastructure base for adoption of spatial multiomics platforms.

The global Spatial Multiomics Market is moderately fragmented, with competition among established life sciences instrument manufacturers, specialized spatial biology platform developers, and bioinformatics and software providers. Companies compete primarily on multiomic capability breadth, spatial resolution, throughput, ease of workflow integration, and the strength of accompanying data analysis and visualization software.

Leading market participants are investing in expanding multiomic capabilities within single platforms, as illustrated by 10x Genomics' Xenium Protein launch and Singular Genomics' G4X platform, alongside strategic partnerships to integrate AI-based spatial data analysis tools. Continued R&D investment in higher-plex, higher-resolution, and higher-throughput spatial multiomics platforms remains a key strategy adopted by major vendors.

The report provides a comprehensive competitive assessment of the leading companies operating in the global Spatial Multiomics Market. The key players profiled in the report include 10x Genomics, Inc., Bruker Corporation, Illumina, Inc., Danaher Corporation, Bio-Techne Corporation, Akoya Biosciences, Inc., Revvity, Inc., Standard BioTools Inc., Vizgen, Inc., Resolve Biosciences GmbH, NanoString Technologies, Inc., BGI Genomics Co., Ltd., Thermo Fisher Scientific Inc., QIAGEN N.V., and RareCyte, Inc.

Key Questions Answered in the Report